Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG Japan
- Development stage
- Phase 4
- Lead developer
- Japan BCG Laboratory
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Percutaneous, Intravesical
01
Overview
BCG Japan, specifically the Tokyo 172 substrain, is a live-attenuated preparation of *Mycobacterium bovis*. It is classified as an "evolutionarily early" substrain, meaning it retains certain genetic regions (such as RD2) that were lost in later-derived strains like Tice or Connaught. Developed and manufactured by the Japan BCG Laboratory, it is used globally both as a vaccine for the prevention of tuberculosis (typically administered percutaneously) and as an intravesical immunotherapy for non-muscle invasive bladder cancer (NMIBC). In the context of bladder cancer, BCG Japan induces a robust local inflammatory response characterized by the recruitment of T cells, natural killer cells, and macrophages, and the production of various cytokines (including IL-6, IL-8, and TNF-alpha), which collectively mediate the destruction of urothelial tumor cells.
- Brand names
- Immuno BCGBCG Vaccine
- Other names
- BCG TokyoMycobacterium bovis BCG Tokyo 172
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on BCG Japan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG Japan.